PRL-8-53

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PRL-8-53
PRL-8-53.svg
Clinical data
Pregnancy
category
  • US: N (Not classified yet)
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: unscheduled
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C18H21NO2
Molar mass 283.36 g/mol
3D model (Jmol)

PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine (Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.[1][2]

Nootropic effects[edit]

A single study in humans was reported in 1978. The double-blind trial of PRL-8-53 in 47 healthy volunteers measured its effects on a variety of cognitive measures. 5 mg of the drug was administered orally 2–2.5 hours before the study tasks.[1] Overall improvements in recollection differed based on how many words were recalled under placebo, with the poor performers (six words or fewer) experiencing a 87.5-105% increase in recollection and the high performers (eight or more words) a 7.9-14% increase which failed to reach statistical significance; when controlling for subjects over the age of 30 only, a 108-152% increase was noted. The researchers noted that this was likely a result of a ceiling effect due to many of their subjects scoring close to 100% on the recall test even on placebo.[1] No side effects were reported during the trial.[1]

Mechanism of action[edit]

The exact mechanism of action of PRL-8-53 remains unknown. Doses up to 200 mg/kg are not observed to have stimulant properties, and a dosage of 20 mg/kg does not potentiate the effects of dextroamphetamine in rats.[1] It displays possible cholinergic properties, and potentiates dopamine while partially inhibiting serotonin. PRL-8-53 reverses the catatonic and ptotic effects of reserpine.[1][3]

Toxicity[edit]

PRL-8-53 is relatively non-toxic, with an oral LD50 in mice of 860 mg/kg, giving the drug a high therapeutic index. Doses above 8 mg/kg have brief hypotensive effects in the canine. High doses depress motor activity in the rat and mouse, with the ED50 for a 50% reduction in motor activity of mice at 160 mg/kg. PRL-8-53 displays spasmolytic effects.[3]

Synonyms[edit]

Methyl 3-(2-(benzylmethylamino)ethyl)benzoate hydrochloride
3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride
3-(2-(Methyl(phenylmethyl)amino)ethyl)benzoic acid methyl ester hydrochloride

See also[edit]

References[edit]

  1. ^ a b c d e f Hansl, NR; Beverley T. Mead (1978). "PRL-8-53: Enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent". Psychopharmacology. 56 (3): 249–253. PMID 418433. doi:10.1007/BF00432846. 
  2. ^ US Patent 3870715 A: Substituted amino ethyl meta benzoic acid esters
  3. ^ a b Hansl, N. R. (1974). "A novel spasmolytic and CNS active agent: 3-(2-benzylmethylamino ethyl) benzoic acid methyl ester hydrochloride". Experientia. 30 (3): 271–272. PMID 4824605. doi:10.1007/BF01934822.